US holds 80% of global vaccine supply with 35% of monkeypox cases: Report

The analysis compared vaccine access and monkeypox cases in more than a dozen countries.

Monkeypox
US holds 80% of global vaccine supply with 35% of monkeypox cases. (Illustration: Reuters)
IANS New York
2 min read Last Updated : Sep 02 2022 | 2:36 PM IST

Amid the shortage of monkeypox vaccines, the US holds nearly 80 per cent of the Jynneos jab used to fight monkeypox, despite having only 35 per cent of the global cases of the virus, a report said on Friday.

According to the Public Citizen analysis, the US has 22 times more doses than the EU and the UK.

"Once again, vaccines for an outbreak are not available in the vast majority of countries, including in the African states that have fought monkeypox for years," Peter Maybarduk, director of Public Citizen's Access to Medicines Programme, said in a statement.

"We still are waiting for President Biden to put forward a plan to fight global monkeypox and avoid the tragic mistakes of the Covid crisis," Maybarduk added.

The analysis compared vaccine access and monkeypox cases in more than a dozen countries.

For example, African countries where monkeypox is endemic, including the Democratic Republic of Congo, neither have access to doses nor orders secured, despite recording multiple deaths.

The report mentioned that no countries in Africa have any doses on hand or any orders placed. And Brazil, which has reported close to one in twelve cases globally, has no doses available.

As of August 25, the US had already obtained 1,100,000 vaccine doses for 16,602 cases -- or 66 doses for every case, with nearly 7 million in total ordered so far.

Earlier this month, advocates urged the Biden administration to use the Defense Production Act to ramp up and accelerate production of additional finished Jynneos vaccine doses and support expansion and diversification of vaccine production capacity globally.

--IANS

vc/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :MonkeypoxUSVaccine

First Published: Sep 02 2022 | 2:36 PM IST

Next Story